Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Neutral Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a report published on Tuesday, MarketBeat.com reports. They currently have a $75.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $72.00.

RARE has been the subject of a number of other research reports. BidaskClub upgraded Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, June 20th. Stifel Nicolaus reiterated a buy rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 30th. Sanford C. Bernstein began coverage on Ultragenyx Pharmaceutical in a research note on Thursday, July 27th. They set a market perform rating and a $72.00 price objective for the company. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a hold rating to a sell rating in a research note on Tuesday, July 11th. Finally, ValuEngine upgraded Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company’s stock. Ultragenyx Pharmaceutical has a consensus rating of Hold and a consensus price target of $84.87.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 59.44 on Tuesday. The company’s market cap is $2.52 billion. The firm’s 50-day moving average price is $64.97 and its 200 day moving average price is $67.17. Ultragenyx Pharmaceutical has a 12-month low of $51.67 and a 12-month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.73) by $0.01. During the same period in the previous year, the business posted ($1.46) EPS. On average, analysts predict that Ultragenyx Pharmaceutical will post ($7.24) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Neutral Rating at HC Wainwright” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/08/12/ultragenyx-pharmaceutical-inc-nasdaqrare-given-neutral-rating-at-hc-wainwright.html.

In related news, VP Theodore Alan Huizenga sold 480 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $57.46, for a total value of $27,580.80. Following the sale, the vice president now directly owns 9,366 shares in the company, valued at approximately $538,170.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 9.20% of the company’s stock.

Large investors have recently bought and sold shares of the company. Hood River Capital Management LLC boosted its stake in Ultragenyx Pharmaceutical by 2.4% in the second quarter. Hood River Capital Management LLC now owns 112,296 shares of the biopharmaceutical company’s stock valued at $6,975,000 after buying an additional 2,667 shares during the last quarter. Teachers Retirement System of The State of Kentucky boosted its stake in Ultragenyx Pharmaceutical by 32.4% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 42,218 shares of the biopharmaceutical company’s stock valued at $2,622,000 after buying an additional 10,320 shares during the last quarter. California Public Employees Retirement System boosted its stake in Ultragenyx Pharmaceutical by 2.1% in the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biopharmaceutical company’s stock valued at $2,429,000 after buying an additional 800 shares during the last quarter. Vanguard Group Inc. boosted its stake in Ultragenyx Pharmaceutical by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company’s stock valued at $194,421,000 after buying an additional 135,335 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Ultragenyx Pharmaceutical by 4.2% in the second quarter. Northern Trust Corp now owns 477,401 shares of the biopharmaceutical company’s stock valued at $29,651,000 after buying an additional 19,138 shares during the last quarter. Institutional investors own 95.40% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

What are top analysts saying about Ultragenyx Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ultragenyx Pharmaceutical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit